One of the more interesting aspects of my role covering innovation trends in emerging markets is the opportunity to see companies close-up as they scale. Such was my recent experience attending a summit held by CSOFT International in Beijing and Sanya, the Hawaii of China.<\/p>\n
CSOFT was celebrating its 10th anniversary with a two-day program of experts speaking about globalization trends in the so-called localization business in which it operates. One clear takeaway? I am sure that CSOFT would never have become a profitable player in this market without the visionary leadership of its very determined president and CEO, Shunee Yee (pictured with me).<\/p>\n
Sounding a bit like Alibaba\u2019s Jack Ma, Shunee says \u201cthe sky\u2019s the limit\u201d on her startup\u2019s potential, which she envisions becoming a $1 billion business. The company\u2019s nifty-looking headquarters at Beijing\u2019s sleek, new World Finance Centre is a symbol of her ambitions.<\/p>\n
Click here to read the whole entry.<\/a><\/p>\n \n CSOFT Health Sciences, leaders in clinical trial localization, provides AI\/ML-enabled medical translation services for all phases of the drug and medical device product lifecycle, from development to post-launch. We also specialize in DCT solutions, linguistic validation, and CTD\/eCTD submissions with the FDA, EMA, and NMPA. Our operations are certified in ISO 17100:2015, ISO 9001:2015, and ISO 13485:2016, ensuring our customized solutions meet the rigorous regulatory requirements of MMA, NDA, CTA, and Medical Device Application submissions. www.csoftintl.com<\/u><\/a><\/p>\n \n <\/div>\n \r\n About CSOFT Health Sciences<\/h3>\n